Theraclone Sciences Closes Another $14 Mln in Financing
Theraclone Sciences said Monday it closed $14 million in additional financing. Existing investors -- ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo -- committed $8 million equity. Another $6 million in venture debt was secured through a credit facility with MidCap Financial and Silicon Valley Bank. Seattle-based Theraclone develops novel therapeutic antibodies for the treatment of infectious disease and cancer.
25 March 2013•2 mins read
